CHARACTERISTICS OF RE-BIOPSIED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS

被引：0

作者：

Arai, Daisuke ^{[1
]}

Soejima, Kenzo ^{[1
]}

Yasuda, Hiroyuki ^{[1
]}

Tani, Tetsuo ^{[1
]}

Kuroda, Aoi ^{[1
]}

Ishioka, Kota ^{[1
]}

Ohgino, Keiko ^{[1
]}

Sato, Takashi ^{[1
]}

Terai, Hideki ^{[1
]}

Ikemura, Shinnosuke ^{[1
]}

Hamamoto, Junko ^{[1
]}

Naoki, Katsuhiko ^{[1
]}

Hayashi, Yuichiro ^{[2
]}

Betsuyaku, Tomoko ^{[1
]}

机构：

[1] Keio Univ, Dept Med, Div Pulm Med, Sch Med, Tokyo 108, Japan

[2] Keio Univ, Dept Pathol, Sch Med, Tokyo 108, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

EGFR mutation; aquired resistance; re-biopsy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.10-039

引用

页码：S581 / S582

页数：2

共 50 条

[31] Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
Adjej, AA
DRUGS OF THE FUTURE, 2001, 26 (11) : 1087 - 1092
[32] Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Jackman, David
Pao, William
Riely, Gregory J.
Engelman, Jeffrey A.
Kris, Mark G.
Jaenne, Pasi A.
Lynch, Thomas
Johnson, Bruce E.
Miller, Vincent A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : 357 - 360
[33] Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny
Kenichi Suda
Hiroshi Mizuuchi
Yoshihiko Maehara
Tetsuya Mitsudomi
Cancer and Metastasis Reviews, 2012, 31 : 807 - 814
[34] Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
Ayoola, Ayodele
Barochia, Amit
Belani, Kiran
Belani, Chandra P.
CANCER INVESTIGATION, 2012, 30 (05) : 433 - 446
[35] Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
Arcila, M. E.
Riely, G. J.
Zakowski, M. F.
Kris, M. G.
Ladanyi, M.
Pao, W.
Miller, V. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[36] Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors
Ruiz-Camps, Isabel
Aguilar-Company, Juan
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (02) : 257 - +
[37] Erlotinib/osimertinibDevelopment of resistance to epidermal growth factor receptor-tyrosine-kinase inhibitors: case report
Reactions Weekly, 2016, 1626 (1) : 74 - 74
[38] A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
Nakamura, Tomomi
Sueoka-Aragane, Naoko
Iwanaga, Kentaro
Sato, Akemi
Komiya, Kazutoshi
Abe, Tomonori
Ureshino, Norio
Hayashi, Shinichiro
Hosomi, Toshiya
Hirai, Mitsuharu
Sueoka, Eisaburo
Kimura, Shinya
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (10) : 1639 - 1648
[39] Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Nagano, Tatsuya
Tachihara, Motoko
Nishimura, Yoshihiro
CELLS, 2018, 7 (11)
[40] Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
Bonomi, Philip D.
Buckingham, Lela
Coon, John
CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4606S - 4612S

← 1 2 3 4 5 →